The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Slide banner

PRMT5 Inhibitor (BAY 3713372)

See how this compound is being investigated across Bayer’s oncology pipeline

Explore the tumor types, areas of research, and clinical trials associated with this investigational compound.

PRMT5-BAY-3713372_Sqrt

Compound Overview

PRMT5 inhibitor (BAY 3713372) is a 5′-methylthioadenosine (MTA)–specific protein arginine methyltransferase 5 (PRMT5) inhibitor that selectively targets methylthioadenosine phosphorylase (MTAP)–deficient cancer cells with high MTA levels, sparing normal cells that have low MTA levels.1,2 It is currently being investigated in a phase I clinical trial of patients with MTAP-deleted solid tumors.1

Tumor Types

Gastrointestinal cancer (pancreatic)
Solid tumors

Area of Research

PRMT5 signaling

Clinical Trial

Tumor Type(s)

Phase

Status

Description

NCT Number

Solid Tumors, Gastrointestinal Cancer (Pancreatic)

I, II

Now Enrolling

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors

NCT06914128

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.